20/20 Biolabs, Inc. (AIDX)
NCM · Medical Devices
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Peers in Healthcare
20/20 Biolabs, Inc. has no peer companies in this window.
Recent press releases
April 2026
20/20 Biolabs, Inc. — 8-K Filing
# 🧾 What This Document Is This is a **Form 8-K filing** with the SEC, which companies use to announce major news to investors. Attached to it is a **press release** from March 31, 2026, detailing 20/20 BioLabs' financial results for all of 2025 and recent business updates. Think of it as the compan
SEC filings
All filings →Insider trades
All insider trades →20/20 Biolabs, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for 20/20 Biolabs, Inc. in this window.
People at 20/20 Biolabs, Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for 20/20 Biolabs, Inc..